Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3721-3729

  Fu, Qiang ^a   Zhang, Guoqiang ^a   Chen, Hongwei ^a   Zheng, Youwei ^a   Cheng, Jing ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Colorectal cancer; Genetic polymorphism; MDM2; Meta analysis; Susceptibility

Indexed keywords

PROTEIN MDM2;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COLORECTAL CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MDM2 GENE; ONCOGENE; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EID: 84891482169     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0956-z     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. American Cancer Society. Cancer facts and figures. 2010. Available: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc024113.pdf
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
4. Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871-6.
5. Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010;40:281-5.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85.
7. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol. 2010;172:1000-14.
8. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 2004;91:1415-19.
9. Chaoliang X, Jun L, Lingxian Y, Yuan H. Methylation of p14ARF and abnormal expression of p53 and MDM2 in colorectal cancer: role and correlation. Sci Res Essays. 2010;5:1669-75.
10. Raina D, Adham R, Chen D, Kumar S, Kharbanda S, Kufe D. MUC1 oncoprotein suppresses activation of the ARF-MDM2-P53 pathways. Cancer Biol Ther. 2008;7:1959-67.
11. Hao XP, Gunther T, Roessner A, Price AB, Talbott IC. Expression of MDM2 and p53 in epithelial neoplasms of the colorectum. Mol Pathol. 1998;51:26-9.
12. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453-9.
13. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991;10:1565-9.
14. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of MDM2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA. 1998;95:15608-12.
15. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96-107.
16. Juven-Gershon T, Oren M. MDM2: the ups and downs. Mol Med. 1999;5:71-83.
17. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
18. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65:5481-4.
19. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: transcriptional activation of MDM2 and induction of p19ARF. Cell. 2000;103:321-30.
20. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human MDM2 gene. Nucleic Acids Res. 1995;23:2584-92.
21. Cao X, Zhang T, Zhao Z, Zhao T. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol. 2012;31:355-9.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
26. Alazzouzi H, Suriano G, Guerra A, Plaja A, Espín E, Armengol M, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet. 2007;44:75-80.
27. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, et al. The MDM2 promoter polymorphism SNP309T- > G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005;42:694-8.
28. Sotamaa K, Liyanarachchi S, Mecklin JP, Järvinen H, Aaltonen LA, Peltomäki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11:6840-4.
29. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;98:285-8.
30. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. MDM2 SNP309 T > G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer. 2007;120:563-5.
31. Liu JN, Zhang XM, Guo YL, Sun T, Lin DX, Wen T. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population]. Zhonghua Zhong Liu Za Zhi. 2008;30:335-8. Article in Chinese.
32. Chen YL, Chang YS, Chang JG, Wu SM. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem. 2009;394:1291-7.
33. Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, et al. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol. 2011;41:232-8.
34. Zhang Y, Liu L, Tang Y, Chen C, Wang Q, Xu J, et al. Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study. Mol Biol Rep. 2012;39:9661-8.
35. Chaar I, Arfaoui TA, El Amine El HO, Mahmoud LB, Khiari M, Sammoud S, et al. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population. Eur J Gastroenterol Hepatol. 2012;24:320-7.
36. Sugano N, Suda T, Godai TI, Tsuchida K, Shiozawa M, Sekiguchi H, et al. MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Genes Chromosomes Cancer. 2010;49:620-9.
37. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA. 2005;102:16297-302.
38. Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet. 2003;112:434-5.
39. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26:1317-23.
40. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet. 2006;43:950-2.
41. Kondo I, Lida S, Takagi Y, Sugihara K. MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum. 2008;51:1395-402.
42. Ray RM, Bhattacharya S, Johnson LR. MDM2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis. 2011;16:35-44.
43. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156:300-10.
44. Hosking L, Lumsden S, Lewis K, Yeo A, McCarthy L, Bansal A, et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet. 2004;12:395-9.
45. Mitchell AA, Cutler DJ, Chakravarti A. Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet. 2003;72:598-610.
46. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840-8.
47. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006;163:300-9.